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Abstract
Background: To evaluate whether PI3K/Akt pathway could effect on apoptosis and its mechanism in nasopharyngeal 
carcinoma cells.
Methods: The activation of the PI3K/Akt and its effect on CNE-2Z cells in vivo and in vitro was investigated by MTT 
assay, flow cytometry, western blot, ELISA, terminal deoxyribonucleotide transferase-mediated nick-end labeling assays 
(TUNEL), and immunohistochemical analyses, using PI3K inhibitor, LY294002.
Results: The results showed that LY294002 inhibited the phosphorylating of Akt (S473), cell proliferation, and induced 
apoptosis in CNE-2Z cells. However, our experiment results also demonstrated that apoptosis-induced LY294002 was 
directly regulated by caspase-9 activation pathway.
Conclusion: These data suggested that PI3K inhibitor, LY294002, induced apoptosis by caspase-9 activation pathway 
and might be as a potentially useful target for therapeutic intervention in nasopharyngeal carcinoma patients.
Background
Nasopharyngeal carcinoma (NPC) has a distinct epide-
miology and distribution, southern China and Southeast
Asia are the highest risk areas, while rare in most parts of
the world. Although many NPC patients may undergo
radiation therapy for possibly cure and new strategies
have improved survival for patients with metastasis, 30%-
40% NPC patients die from local recurrence and metasta-
sis. A better understanding of signaling pathways contrib-
uting to NPC survival and apoptosis will provide targets
for new therapeutic agents.
The phosphatidylinositol-3 OH kinase (PI3K)/Akt sig-
naling pathway has been shown to contribute to cancer
survival, apoptosis, and regulating a variety of cellular
processes. In particular, Akt serine/threonine kinase is
believed to play a critical role in controlling the balance
between cell survival and apoptosis [1]. Previous studies
had shown that phosphatidylinositol 3,4,5-trisphos-
phate(PIP3) generated by PI3K acts as a lipid second mes-
senger essential for the translocation of protein kinase
B(Akt) to the plasma membrane [2,3]. Akt is phosphory-
lated at two sites, T308 in kinase domain and S473 in reg-
ulatory tail. Phosphorylation at T308 and S473 is
essential for maximal Akt activation [2,3]. Phosphory-
lated Akt regulates the function of a broad array of intrac-
ellular proteins involve in fundamental processes
including cell proliferation, cell death, cell motility/adhe-
sion, cell transformation, neovascularization, and the
inhibition of apoptosis [2-5]. PIP3 levels and Akt activa-
tion are regulated by the action of phosphatase and tensin
homologue deleted from chromosome 10(PTEN). The
Akt survival pathway is regulated negatively by PTEN
lipid phosphatase, which selectively dephosphorylates the
3' site on polyphosphoiositides produced by PI3K [6,7].
Alterations of the PI3K/Akt pathway in human carcino-
mas have been reported [8-10]. Many studies demon-
strated that PI3K/Akt pathway is constitutively activated
in various cancers, including gastric, renal cell, ovarian,
and lung cancers, and plays a critical role in tumor forma-
tion [9-12]. There is now convincing evidence that the
alterations of the PI3K/Akt pathway is related not only to
tumor progression but also to human resistance to radia-
tion and systemic therapies.
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LY294002 (2-4-morpholinyl-8-phenlchromone) is
chemical inhibitor of PI3K, which has been used exten-
sively to study the role of PI3K/Akt pathway in normal
and transformed cells [13,14]. Inactivation of PI3K using
LY294002 has been demonstrated to lead to the dephos-
phorylation of Akt at both T308 and S473, consequently
inducing specific G1 arrest in cell growth and finally to
cell apoptosis [15,16]. The inhibitors of PI3K also have
antitumor activity in vitro and  in vivo in a variety of
tumor types [12,17-19], and it is possible that cells
expressing constitutively active Akt become dependent
on its survival-promoting effects. Although these results
have been observed in many human cancers [18-20], the
role of LY294002 in human nasopharyngeal carcinoma
has not been well documented yet.
To evaluate the significance of Akt phosphorylation in
proliferation and apoptosis of human nasopharyngeal
carcinoma, we investigated the role of Akt phosphoryla-
tion and the effect of LY294002 in vitro and in vivo. Our
goal was to confirm that the PI3K/Akt pathway might be
a new therapeutic target on clinic treatment for nasopha-
ryngeal carcinoma patients.
Methods
Cell culture
Human nasopharyngeal carcinoma cell line CNE-2Z was
from Pathological Department of Guangdong Medical
College. Cells were cultured in RPMI-1640 (Gibco, USA)
supplemented with 10% fetal bovine serum(Gibco, USA),
1% penicillin-streptomycin (Life Technologies) at 37°C in
a humidified incubator with a 5% CO2 atmosphere.
Cell proliferation assay
The cells were seeded into 96-well plates(Corning, Low-
ell, MA, USA) at 5000 cells/well. Twenty-four hours after
cells were seeded, the medium was removed and replaced
in the presence of LY294002 (0 μmol/L, 10 μmol/L, 25
μmol/L, 50 μmol/L, and 75 μmol/L) dissolved in DMSO
or DMSO only for an additional 24 h and 48 h. To avoid
any nonspecific toxic effects of DMSO on cell growth,
DMSO concentrations were maintained at 0.5% in all
experiments. MTT dye (5 mg/mL, Sigma, Saint Louis,
MO, USA) was added to each well. The reaction was
stopped by the addition of DMSO(Sigma), and optical
density was measured at 490 nm on a multiwell plate
reader. Background absorbance of the medium in the
absence of cells was subtracted. All samples were assayed
in triplicate, and the mean for each experiment was cal-
culated. Results were expressed as a percentage of con-
trol, which was considered to be 100%.
Annexin V/PI for cell apoptotic analysis
Cells were collected with 0.25% trysin/0.02% EDTA after
presence of LY294002(0 μmol/L, 10 μmol/L, 25 μmol/L,
50 μmol/L, and 75 μmol/L)24 h and 48 h. At the same
time, caspase-9 specific inhibitor, ZVAD(0 μmol/L, 5
μmol/L, 10 μmol/L, 20 μmol/L), was added for 48 h. Cells
were harvested at the end of treatment, rinsed twice with
PBS, and stained with Annexin V-FITC apoptosis detec-
tion kit I (BD Biosciences). Analysis was performed on
the FACS Calibur using CellQuest software.
P-Akt ELISA assay
CNE-2Z cells were plated on 6-well plates in RPMI-1640
plus 10% FBS in duplicate for each treatment. Chemical
inhibitor LY294002 was added to the appropriate wells.
The cells were incubated at 37°C for 24 h and 48 h. Phos-
phorylated protein level of treated and untreated cells
lysates was measured using a commercially available
ELISA kit. Statistical analysis to determine significance of
the observed differences was used by the Linear Regres-
sion. Experiments were repeated three times.
Western blot analysis
Cells were homogenized in 500 μl with lysis buffer (1%
Triton X-100, 50 mM Tris-HCL (Ph7.5), 0.1% SDS, 150
mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM PMSF, 0.1
mM Na V04, 0.1 mM benzamidine, 5 μl/ml leupeptin, 5
μl/ml aprotinin). The lysates were clarified by centrifuga-
tion at 12000 g for 15 min at 4°C. Samples were analyzed
by 15% SDS-polyacrylamide gels, and transferred to
nitrocellulose membranes, and the membranes was incu-
bated with primary antibodies, followed by horseradish
peroxidase-cunjugated secondary antibodies. An anti-
body for β-actin was used as a loading control.
Tumor xenograft experiments
All of the experiments involving animals in present study
were approved by the animal center of Guangdong Medi-
cal College in accordance to institutional and Guangdong
government guidelines for animal experiments. Athymic
nude mice were used when they were 6-8 weeks. Mice
were randomly divided into free separated into five
groups (n = 4 mice). Mice were housed in the same envi-
ronment with controlled temperature, humidity, and a 12
h light/dark cycle. Mice were inoculated subcutaneously
with CNE-2Z cells (1 × 106  cells/mouse in 200 μl of
RPMI-1640) into the flank. The tumor take rate was
100%. After 1 week, an intraperitoneal injection was per-
formed to the xenograft mice with different dosage of
LY294002 (10 mg/kg, 25 mg/kg, 50 mg/kg, and 75 mg/kg
twice weekly (n = 4 mice), each group for 4 weeks.
Treated mice were monitored any signs. Body weight and
tumors size were measured twice a week. Tumor size was
measured using calipers and tumor volume was calcu-
lated (volume = long axis × short axis2). At the end of the
treatment, all mice were euthanized. One part of tumorJiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:34
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tissue was fixed in formalin and embedded in paraffin,
and another part was stored at -70°C.
Immunohistochemistry analysis
P a r a f f i n  s e c t i o n s  w e r e  u s e d  f o r  i m m u n o h i s t o c h e m i c a l
analysis of Akt, p-Akt, caspase-9, Ki67, and the TUNEL
method for determining of DNA fragmentation. TUNEL
assay was carried out according to the protocol of the
ApopTag Peroxidase in situ apoptosis detection kit
(Chemicon International, Temecula, Calif, USA). Positive
expression of Akt, p-Akt, and caspase-9 locates in the
cytoplasm. Immunohistochemical expression of Ki67 and
TUNEL-positive cells shows in the nuclei. The mean per-
centage of positive tumor cells was determined from five
areas at highpower field (×400). The growth index (GI)
and the apoptosis index (AI) were calculated by counting
the Ki67- and TUNEL-positive cells in a total of 1000
tumor cells observed from more than representative
highpower fields, respectively. Immunohistochemical
results were evaluated independently.
Statistical analysis
Data were expressed as mean ± SD of mean and com-
pared by unpaired Student's t test. ELISA Assay was used
by the Linear Regression. Results were considered signifi-
cant at a value of P < 0.05.
Results
Effects of PI3K/Akt inhibition on proliferation and 
apoptosis of NPC cells
To determine whether inhibition of PI3K/Akt activ-
ity(LY294002) would inhibit cell proliferation and pro-
mote apoptosis in CNE-2Z cell line, MTT assay and flow
cytometry analysis were used. When the cells were cul-
tured in medium containing different concentrations of
LY294002 for 24 h and 48 h, cell proliferation was
remarkably decreased in a dose-dependent fashion (Fig
1). The Annexin V/PI assay was used to detect apoptosis
in NPC cells. As shown in Fig 2A, the proportion of apop-
totic cells was significantly increased in dose-dependent.
Caspase-9 is regarded as a most likely candidate relating
with apoptosis-induced by PI3K inhibitor [21], we
explored whether caspase-9 was involved in LY294002-
induced cell apoptosis in CNE-2Z cells by detecting cas-
pase-9 activity in cells treated with PI3K/Akt inhibitor.
When caspase-9 specific inhibitor, ZVAD, was added,
apoptosis rate was decreased at 48 h (Fig 2B).
Effects of PI3K/Akt inhibition on Akt phosphorylation in 
NPC Cells
When LY294002 was added to NPC cells with different
concentrations, levels of phosphorylation (S473) Akt
were decreased in treated NPC cells, exhibiting a dose-
response effect (Table 1).
Effects of PI3K/Akt inhibitionon protein expression in NPC 
cells
The results of Western blot showed that total Akt protein
level was not difference with different concentration. In
contrast, phosphorylated Akt (S473) expression levels
were significantly decreased in treated group. At the
same time, we explored whether caspase-9 was involved
in LY294002- induced cell apoptosis in CNE-2Z cells by
detecting caspase-9 activity in cells treated with PI3K/
Akt inhibitor. The results show caspase-9 activity in Figure 1 CNE-2Z cells growth rate in different concentrations of 
LY294002.
Figure 2 CNE-2Z cells apoptosis rate. CNE-2Z cells apoptosis rate in-
duced by different concentrations of LY294002. B. CNE-2Z cells apop-
tosis inhibited by different concentrations of ZVAD (0, 5, 10, and 20 
μmol/L) at 48 h.Jiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:34
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CNE-2Z cells was up-regulated by LY294002, whereas the
level of caspase-9 was not changed after using ZVAD (Fig
3).
Effects of PI3K/Akt inhibition proliferation and apoptosis in 
vivo
Tumors generated by orthotopic implantation of the met-
astatic CNE-2Z cell line were used to evaluate the effect
of LY294002 on proliferation and apoptosis in an orthoto-
pic xenograft model. All of the mice were sacrificed after
4 weeks of treatment. Treatment with LY294002 (50 mg/
kg, 75 mg/kg) significantly reduced mean NPC tumor
burden as compared with the control group (LY294002
50 mg/kg, 75 mg/kg; P < 0.001). Treatment with 10 mg/kg
or 25 mg/kg LY294002 was less effective in decreasing
tumor burden. Mean NPC tumor burden treated with
LY294002 was remarkably decreased in a dose-dependent
manner, whereas mean body weight was no obvious dif-
ference between control and treated groups (LY294002
10 mg/kg, 25 mg/kg, 50 mg/kg, and 75 mg/kg; P > 0.05;
Fig 4A and 4B). Compared with control, TUNEL-positive
cells treated with LY294002 were significantly increased
in a dose-dependent fashion (Fig 4C and 4D), with signif-
icant difference (P < 0.01).
Immunohistochemical studies for xenograft tumor tissues
Finally, the histological examination and immunohisch-
emistry were performed to determine the biological
influence of LY294002 on tumor morphology, prolifera-
tion, apoptosis, and expression of Akt, phosphorylated
Akt. The histological changes showed that tumor cells of
treated groups were more necrosis than those of control
group (Fig 5A). Compared with control group, the
expression of phosphorylated Akt was significantly
decreased in treated with LY294002 (Fig 5B). Results of
immunohistochemical staining with Ki67 and caspase-9
support the gross observations. A great many of NPC
cells from the control group stained positive Ki67 (Fig
5C). The number of proliferation cells treated with
LY29400 showed significant reduction in a dose-depen-
dent manner (Fig 5D), with significant difference (P <
0.05; P < 0.01). The expression of caspase-9 appeared to
have an obvious increase in the groups treated with
LY294002 (Fig 5E). No significant difference was found
between the expression of Akt in tumor from the control
and LY294002-treated mice.
Discussion
The PI3K/Akt cascade is known to be an important sur-
vival factor in the signal transduction cascades involved
in the cell survival and apoptosis. PI3K is one of the core
intracellular signaling molecules in the stimulation of
growth factors, subsequently phosphorylating and acti-
vating Akt. This signaling pathway cascades activated by
some other factors play a critical role in regulating tumor
cell growth, survival, motility, invasion, and differentia-
tion. Although there has been a rapid expansion in the
number of identified physiological Akt substrates that are
involved in various aspects of cellar function, there are
clearly candidates that are directly involved in the regula-
tion of apoptosis [2]. Akt can suppress apoptosis by
directly interacting with and phosphorylating these
proapoptotic proteins. This cascade is thus an exciting
new target for molecular targeting therapy for cancer.
Our results show that LY294002 markedly inhibited NPC
CNE-2Z cell growth, proliferation, and induced apoptosis
in vitro and in vivo.
Previous studies have demonstrated that the expression
of phosphorylated Akt had a closely correlated to cell
growth, proliferation, and resistance to apoptosis
[9,15,22-25]. In addition, LY294002, the PI3K/Akt spe-
cific inhibitor, showed the growth-inhibitory effects due
to cell-cycle arrest closely correlated to with the accumu-
lation of cyclin-dependent kinase inhibitors p27 and
Figure 3 Western blot analysis of Akt, phosphor-Akt(S473), cas-
pase-9, and caspase-9 treated with ZVAD (20 μmol/L). N: no treat-
ment group; Lanes1, 2, 3, and 4: treatment with LY294002(10 μmol/L, 
25 μmol/L, 50 μmol/L, and 75 μmol/L respectively).
Table 1: Expression of p-Akt protein in CNE-2Z cells treated 
with LY294002
LY294002 (mol/L) n P-Akt(unit/ml)
0 3 74.10 ± 1.00
10 3 62.65 ± 0.68
25 3 50.09 ± 1.83
50 3 25.22 ± 1.83
75 3 13.21 ± 1.34
F 1328.43
P < 0.001Jiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:34
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PTEN [6,7,26,27]. Some studies found that PI3K inhibi-
tors produce apoptosis and antiproliferative effects on
pancreatic carcinoma cells in vivo and in vitro [15,23].
T o evaluate the role of Akt in the biology of NPC, we
used immunoblotting to analyse the relationship between
phosphorylation-specific antibody to demonstrate Akt
activity in cultured cells and then confirmed the ability of
the LY294002 to decrease Akt phosphorylation in NPC
cell line and xenograft tumor tissue. We examined the
effect of LY294002 on cell proliferation and the induction
of apoptosis. However, there was a great discrepancy
between the sensitivity to LY294002 and the level of
expression of phosphorylated Akt. The degree of CNE-
2Z cell proliferation and apoptosis was shown in a dose-
dependent fashion. Western blot results revealed
decreasing of phosphorylated Akt levels with increasing
dose of LY294002. In tumor sections from athmic mice,
the necrotic region treated with a higher dose LY294002
(50 mg/kg and 75 mg/kg) was more great than those of
the lower dose (10 mg/kg, 25 mg/kg) of LY294002 and the
control group. The mean body weight did not exhibit sig-
nificant differences between the groups treated with
LY294002 and control group. However, compared with
LY294002 (10 mg/kg, 25 mg/kg) and control group, the
mean tumor burden was remarkably decreased in treated
with LY294002 (50 mg/kg, 75 mg/kg) group, with signifi-
cant difference.
Because the PI3K/Akt signaling pathway plays an
important role in many aspects of cellular homeostasis
[1,4], it is necessary concern that PI3K inhibitor would
interfere with the survival and proliferation of critical
populations of normal cells and show unacceptable toxic-
ity. Previous experiments have testified that it was safe
biweekly i.p. administration of under to 100 mg/kg of
LY294002 [15]. The dose (50 mg/kg and 75 mg/kg) of
LY294002 produced obvious inhibition of Akt phospho-
Figure 4 Growth and apoptosis analysis of tumors xenografts in athymic nude mice. A. Mean body weight and NPC tumor burden treated with 
LY294002. B. Upper: treatment with LY294002(75 mg/kg); Under: no treatment group. C. Representative areas are shown (× 400 magnification). 
TUNEL-positive cells in orthotopic tumor xenografts (Lift: no treatment group; Right: treatment with 75 mg/kg LY2940020). D. Apoptosis rate induced 
by different concentrations of LY294002 in tumors xenografts in athymic nude mice.Jiang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:34
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rylation, reduced tumor cell proliferation, and increased
apoptosis in orthotopic CNE-2Z NPC xenografts.
Akt specific inhibitor, LY294002, did not cause obvious
apoptosis at 24 h exposure, but induced greatly apoptosis
in 48 h in a time-dependent manner. Some studies have
clearly shown that Akt phosphorylates and inactivates
cspase-9, an important initiation caspase of the mito-
chondria pathway-mediated apoptosis [21,28]. Our data
indicated that the caspase-9 inhibitor ZVAD completely
blocked apoptosis induced by PI3K inhibitor, and sug-
gested that AKT conferred resistance to LY294002-
induced apoptosis ultimately through suppressing cas-
pase activation pathways in CNE-2Z cells. The results of
specific caspase inhibitor demonstrated that blocking
caspase-9 pathway exerted a much greater protective
effect against apoptosis.
Conclusion
In summary, Akt played a critical role in regulating the
sensitivity of CNE-2Z cells to the induction of apoptosis
by LY294002. This kinase pathway conferred resistance
by suppressing caspase-9 cascade.
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